Business
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million Positive interim results for
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nSecond quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million\n\n\n\nPositive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies\n\n\n\nLIVMARLI for treatment of PFIC granted marketing authorization in Europe\n\n\n\nInitiating LIVMARLI EXPAND study for pruritus in rare cholestatic conditions\n\n\n\nConference call to provide business updates today, August 7 at 1:30 p.m. PT/4:30 p.m. ET\n\n\n\n FOSTER CITY, Calif.--(BUSINESS WIRE)--\nMirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for second quarter 2024 and provided a business update.\n\n\n“The second quarter was marked by significant achievements across both our commercial medicines and development pipeline as we continued to execute on our strategic priorities,” said Chris Peetz, chief executive officer of Mirum. “The positive interim results of volixibat in the VISTAS PSC and VANTAGE PBC studies are exciting steps towards potential new treatment options for patients suffering from these rare liver diseases. We also achieved key regulatory milestones expanding access to LIVMARLI for patients with PFIC beginning with an approval in Europe for patients three months and older and a label expansion in the US to include patients 12 months and older, and we filed a new drug application for chenodiol in CTX. Finally, we are exploring LIVMARLI’s potential to treat cholestatic pruritus in other indications with the initiation of the EXPAND study.”\n\n\nCommercial: Strong growth across all three approved medicines\n\n\n\nSecond quarter 2024 global net product sales of $77.8 million grew 139% compared to the second quarter 2023.\n\n\n\nLIVMARLI second quarter net sales were $47.2 million, representing 45% growth compared to the second quarter 2023.\n\n\n\nSecond quarter 2024 CHOLBAM and CHENODAL net sales were $30.5 million.\n\n\n\nRegulatory and Pipeline: Achieved significant milestones and expanding pipeline\n\n\n\nPositive Interim results for volixibat in the VISTAS PSC and VANTAGE PBC studies.\n\n\n\nLIVMARLI approved in Europe for PFIC in patients three months and older.\n\n\n\nLIVMARLI approved in the US for cholestatic pruritus in PFIC in patients 12 months and older.\n\n\n\nInitiating the Phase 3 EXPAND study, a label expansion opportunity for LIVMARLI in additional setting...